Match each clinical presentation of infective endocarditis with the most appropriate targeted antimicrobial regimen based on current consensus guidelines.
- A 45-year-old man with native valve infective endocarditis caused by Enterococcus faecalis.Intravenous ampicillin and ceftriaxone
- A 65-year-old man with prosthetic valve endocarditis diagnosed 3 months after valve replacement, caused by methicillin-resistant Staphylococcus epidermidis.Intravenous vancomycin, rifampin, and gentamicin
- A 30-year-old woman with a history of injection drug use presenting with right-sided native valve endocarditis caused by methicillin-susceptible Staphylococcus aureus (MSSA).Intravenous nafcillin or cefazolin
- A 72-year-old man with native valve endocarditis caused by highly penicillin-susceptible Streptococcus gallolyticus (S. bovis).Intravenous aqueous crystalline penicillin G or ceftriaxone
Answer
Enterococcus faecalis is matched with ampicillin and ceftriaxone; methicillin-resistant Staphylococcus epidermidis on a prosthetic valve is matched with vancomycin, rifampin, and gentamicin; methicillin-susceptible Staphylococcus aureus is matched with nafcillin or cefazolin; and Streptococcus gallolyticus is matched with aqueous crystalline penicillin G or ceftriaxone.
Each pathogen and valve combination has a highly specific guideline-directed regimen designed to optimize bactericidal activity, minimize toxicity, and penetrate biofilms when foreign material is present.
Step-by-Step Solution
Key Concept
Targeted antimicrobial therapy for infective endocarditis is determined by the specific pathogen, resistance profile, and presence of native versus prosthetic valves.
Estimated Time:1m 30s